#1 Clinical Trials Search in Europe

Tildrakizumab

This article explores the use of Tildrakizumab, a monoclonal antibody that targets interleukin-23, in various clinical trials. These studies aim to evaluate its effectiveness and safety in treating conditions such as psoriasis, vitiligo, and graft-versus-host disease. The trials assess different aspects of patient outcomes, including disease severity, quality of life, and overall well-being.

Table of Contents

What is Tildrakizumab?

Tildrakizumab, also known by the brand name Ilumetri[1] or Ilumya[5], is a medication used to treat various skin conditions. It belongs to a class of drugs called interleukin-23 (IL-23) inhibitors. Interleukins are proteins in your body that help regulate your immune system. By blocking IL-23, Tildrakizumab helps reduce inflammation in your skin[3].

What Conditions Does Tildrakizumab Treat?

Tildrakizumab is primarily used to treat the following conditions:

  • Moderate to severe plaque psoriasis: This is a chronic skin condition that causes red, scaly patches on the skin[1].
  • Genital psoriasis: A specific form of psoriasis that affects the genital area[1].
  • Nail psoriasis: Psoriasis that affects the fingernails and toenails[10].
  • Vitiligo: A condition where patches of skin lose their color[7].

Researchers are also studying Tildrakizumab’s potential in treating other conditions, such as preventing graft-versus-host disease in patients undergoing stem cell transplants for blood cancers[6].

How Does Tildrakizumab Work?

Tildrakizumab is a monoclonal antibody, which is a type of protein designed to target specific substances in the body. In this case, Tildrakizumab targets and blocks a protein called interleukin-23 (IL-23). IL-23 plays a role in causing inflammation in conditions like psoriasis. By blocking IL-23, Tildrakizumab helps reduce inflammation and improve symptoms of these skin conditions[3].

How is Tildrakizumab Administered?

Tildrakizumab is typically given as a subcutaneous injection, which means it’s injected just under the skin. The usual dosing schedule is:

  • Initial doses at Week 0 and Week 4
  • Followed by maintenance doses every 12 weeks[2]

However, the exact dosing may vary depending on the condition being treated and the individual patient’s needs. Always follow your doctor’s instructions regarding dosing and administration.

Effectiveness of Tildrakizumab

Clinical trials have shown Tildrakizumab to be effective in treating various skin conditions:

  • For plaque psoriasis, many patients see significant improvement in their skin symptoms, measured by scales such as the Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA)[9].
  • For genital psoriasis, Tildrakizumab has shown promise in reducing symptoms and improving quality of life[1].
  • In nail psoriasis, Tildrakizumab may help improve the appearance and health of affected nails[10].
  • For vitiligo, researchers are studying whether Tildrakizumab can help stop the spread of depigmentation and promote repigmentation[7].

Potential Side Effects

Like all medications, Tildrakizumab can cause side effects. Common side effects may include:

  • Upper respiratory infections
  • Injection site reactions (such as redness or pain at the injection site)
  • Headache

More serious side effects, though rare, may include:

  • Severe infections
  • Allergic reactions
  • Increased risk of certain types of cancer[10]

Always discuss potential side effects with your healthcare provider before starting treatment.

Ongoing Research

Researchers continue to study Tildrakizumab to better understand its effects and potential uses. Some areas of ongoing research include:

  • Its impact on cardiovascular health in patients with psoriasis[5]
  • Its effectiveness in preventing graft-versus-host disease in stem cell transplant patients[6]
  • Its long-term safety and effectiveness in real-world clinical settings[8]
  • Its potential in treating vitiligo[7]

These ongoing studies may lead to new uses for Tildrakizumab in the future and help doctors better understand how to use this medication to help patients with various conditions.

Condition Study Type Key Outcomes Measured Duration
Genital Psoriasis Observational sPGA-G, mGPASI, GPSS, DLQI 52 weeks
Pediatric Plaque Psoriasis Randomized Controlled Trial PASI, PGA, CDLQI 88 weeks
Plaque Psoriasis (Adult) Observational WHO-5, DLQI, PASI 28 weeks
Coronary Microvascular Function in Psoriasis Single-arm Open-label Coronary flow reserve, Myocardial blood flow 24 weeks
Graft-versus-host Disease Prevention Phase II Open-label GVHD-free Relapse-Free Survival 1 year
Vitiligo Pilot Study VASI, VES, Repigmentation percentage 24 weeks

FAQ

  • What is Tildrakizumab? Tildrakizumab is a monoclonal antibody that specifically targets interleukin-23 (IL-23), a protein involved in inflammation. It is FDA-approved for treating moderate to severe plaque psoriasis and is being studied for other conditions.
  • What conditions are being studied with Tildrakizumab in clinical trials? Clinical trials are exploring Tildrakizumab's potential in treating various conditions, including plaque psoriasis, genital psoriasis, vitiligo, graft-versus-host disease, and its effects on coronary microvascular function in psoriasis patients.
  • How is the effectiveness of Tildrakizumab measured in these trials? The effectiveness is measured using various scales and assessments, such as the Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and specific measures for each condition being studied.
  • Are there any side effects associated with Tildrakizumab in these trials? While specific side effects are not detailed in the provided information, the trials are monitoring for adverse events and treatment-emergent adverse events (TEAEs) to assess the safety profile of Tildrakizumab.
  • How long do these clinical trials typically last? The duration of the trials varies, ranging from 24 weeks to 24 months, depending on the specific study and condition being investigated.

Ongoing Clinical Trials on Tildrakizumab

  • Study of tildrakizumab to treat patients with chronic spontaneous urticaria who did not respond to previous treatments

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Tildrakizumab and Etanercept for Children Aged 6 to 17 with Moderate to Severe Plaque Psoriasis

    Recruiting

    4 1 1
    Investigated drugs:
    Hungary Poland Slovakia Spain

  • Study of Tildrakizumab for Eye Problems in Patients with Lyell Syndrome

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Tildrakizumab for Patients with Moderate to Severe Genital Psoriasis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Hungary Poland

  • Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

    Not recruiting

    3 1 1
    Investigated drugs:
    Czechia Estonia Germany Italy Poland Slovakia +1

  • Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Not Used Anti-TNF Therapy

    Not recruiting

    3 1 1
    Investigated drugs:
    Czechia Germany Poland Spain

  • Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Czechia Estonia Germany Italy Poland Slovakia +1

Glossary

  • Tildrakizumab: A humanized monoclonal antibody that specifically binds to the IL-23p19 subunit of IL-23 to neutralize its function, used in treating psoriasis and being studied for other conditions.
  • Psoriasis Area and Severity Index (PASI): A measure used to assess the severity and extent of psoriasis, combining the severity of lesions and the area affected into a single score.
  • Dermatology Life Quality Index (DLQI): A questionnaire used to measure the impact of skin diseases on a patient's quality of life, with scores ranging from 0 to 30.
  • Physician's Global Assessment (PGA): A tool used by healthcare providers to evaluate the overall severity of a patient's condition, often used in psoriasis and other skin conditions.
  • Interleukin-23 (IL-23): A protein involved in the body's inflammatory response, which is targeted by Tildrakizumab to reduce inflammation in conditions like psoriasis.
  • Graft-versus-host disease (GVHD): A complication that can occur after a stem cell or bone marrow transplant, where the donated cells attack the recipient's body.
  • Vitiligo: A condition where the skin loses its pigment cells (melanocytes), resulting in white patches on the skin and hair.
  • World Health Organization Well-Being Index (WHO-5): A short questionnaire used to assess subjective psychological well-being, consisting of five items.
  • Coronary flow reserve (CFR): A measure of the heart's ability to increase blood flow in response to stress or exercise, used as an indicator of coronary artery health.
  • Body Surface Area (BSA): A measurement used to determine the extent of skin involvement in conditions like psoriasis, expressed as a percentage of the total body surface area affected.

References

  1. https://clinicaltrials.gov/study/NCT06029257
  2. https://clinicaltrials.gov/study/NCT03997786
  3. https://clinicaltrials.gov/study/NCT06488170
  4. https://clinicaltrials.gov/study/NCT06030076
  5. https://clinicaltrials.gov/study/NCT04271540
  6. https://clinicaltrials.gov/study/NCT04112810
  7. https://clinicaltrials.gov/study/NCT04971200
  8. https://clinicaltrials.gov/study/NCT04823247
  9. https://clinicaltrials.gov/study/NCT04203693
  10. https://clinicaltrials.gov/study/NCT03897075